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PREFACE
The main body of this work is a manuscript entitled “Incorporation of wound
healing agents from chitosan sponges to promote healing of diabetic foot ulcers” which is
to be submitted to the Journal of Biomedical Materials Research Part B.

iv

!

ABSTRACT
Baldwin, Jennifer Leigh. MS. The University of Memphis. December 2013.
Local delivery of growth stimulators for diabetic foot ulcers: A preliminary in vitro study.
Major professor: Dr. Warren O. Haggard
Diabetic foot ulcers affect approximately 15% of the almost 20.8 million people
with diabetes mellitus, costing approximately $10.9 billion annually. Diabetic foot ulcers
are particularly difficult to treat due to neuropathy and healing deficiencies. The objective
of this in vitro study was to measure the effects of adenosine and glutathione on
fibroblast proliferation and collagen synthesis while improving the availability of these
compounds at the wound site with the use of a chitosan sponge as a localized delivery
vehicle. This study found adenosine (500 µM) and glutathione (250 µM) enhanced
fibroblast proliferation by approximately 100% and 46% increase as compared to
untreated controls respectively, and enhanced collagen synthesis in normal fibroblasts.
Furthermore, chitosan sponges effectively released active concentrations of adenosine
and glutathione, up to 500 µM and 250 µM respectively, over a period of three days. The
results of this study suggest that chitosan sponges loaded with adenosine and glutathione
may be effective in treating diabetic foot ulcers in patients under closely managed
glucose conditions.
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CHAPTER 1
INTRODUCTION
1.1 Statement of Clinical Problem
Of the 20.8 million people in the United States with diabetes mellitus, 15% are
affected by diabetic foot ulcers.1-4 Approximately 624,000 of diabetic foot ulcers end in
lower extremity amputations, and the five-year survival rate post-amputation is an
estimated 31%.1-6 Diabetic ulcerations and amputation costs the U.S. almost $10.9 billion
annually in healthcare.7,8 Diabetic foot ulcers are particularly difficult to treat due to
neuropathy and healing deficiencies. It is imperative that more effective, cost efficient
clinical treatments be developed.
1.2 Research Study Objective
In this preliminary study, adenosine, an important component in signaling and a
regulator of fibroblast growth, and glutathione, a strong nucleophile and antioxidant in
the body, were investigated as promising therapeutic agents to produce enhanced
fibroblastic response when applied to normal and “diabetically induced” in vitro cell
cultures. It is expected that glutathione may be effective in reducing the oxidative stress
on fibroblasts caused by hyperglycemia, while adenosine may enhance the proliferation
and restore the function of fibroblasts effected by the diabetic pathology. This
preliminary study also evaluated local drug delivery of these agents to be used in
conjunction with wound dressings at the site of diabetic foot ulcerations. Chitosan, in a
sponge form, has been developed as a local drug delivery vehicle in previous studies and
was used in these investigations.9,10 Our hypothesis was that chitosan can be used to
effectively deliver adenosine and glutathione locally to a diabetic wound site as a
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potential therapeutic method for enhancing fibroblastic function and promoting wound
healing.
1.3 Background
Diabetes mellitus affects approximately 20.8 million people annually in the U.S.
alone.1,11 Almost 15% of these diabetic patients will suffer from a diabetic foot ulcer with
20% of foot ulcers ending in amputation.1-4 The five-year survival rate for a diabetic
amputee is 31%.5,6 The annual cost of healthcare for diabetic foot ulcer complications has
been estimated as high as $10.9 billion.7,8,12 Diabetic foot ulcers are difficult to treat due
to the neuropathy and insufficient vascularization associated with the disease.13
Reduction of the fatty pad, in combination with a decreased perception of pain, may also
impair weight-bearing, thereby causing excessive stresses on the foot and eventually
ulceration or further injury to a previous ulcer.13,14 Complications and the reduction of
important natural growth promoting compounds, such as vascular epithelial growth
factors, platelet derived growth factors, adenosine, and glutathione, impairs healing and
causes difficulties in the treatment of diabetic foot ulcers.15,16-18
Initially, foot ulcerations may be caused by several factors associated with
diabetes mellitus. The neuropathy and peripheral vascular disease associated with
diabetes are major contributing factors to the development of ulceration.19,20 The presence
of hyperglycemia also increases the likelihood that an individual will develop a foot
ulceration.21,22 Table 1 shows a list of common risk factors for development of foot
ulceration and infection in diabetic patients.19 When a patient does develop an ulceration,
further complications may ensue due to a lack of protective sensation caused by
neuropathy intrinsic in the disease.3,13,23 Often, diabetic patients also suffer from poor
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Table 1. Risk factors for development of foot ulceration and infection modification from Lipsky et al.23
Risk factor
Peripheral motor neuropathy

Mechanism of injury
Abnormal foot anatomy and biomechanics, leading to excess
pressure, callus formation, and ulcers
Peripheral sensory neuropathy
Lack of protective sensation, leading to continued reinjury of
minor injuries and enventually major foot ulceration
Peripheral autonomic neuropathy
Deficient sweating leading to dry, cracking skin
Neuro-osteoarthropathic deformities Abnormal anatomy and biomechanics, leading to excess
or limited joint mobility
pressure, primarily in the midplantar area
Vascular insufficiency
Impaired tissue viability and wound healing
Hyperglycemia and other metabolic Impaired immunological function and wound healing
irregularities
Patient disabilities
Reduced vision, limited mobility, and previous amputation(s)
Maladaptive patient behaviors
Poor compliance with medical care, inappropriate activities,
excessive weight-bearing, and poor footwear
Health care system failures
Inadequate patient education and monitoring of glycemic
control and foot care

vascularization, especially in the lower extremities.3,13 This pathology leads to an
inability for the proper growth factors and other growth promoting compounds to be
transported to the wound site to assist in maintaining tissues and tissue repair. As the
disease progresses, these complications may lead to a loss of integrity of the fat pad and
skin on the bottom of the foot, which may lead to wound formation.13,23,24 Since
neuropathy in the lower extremities causes a loss of pain sensation, the forming wound
may go unnoticed and untreated for weeks.3,13,19 Often, the wound goes unnoticed and
progresses until it has already become a fully involved, infected, foot ulceration.
The pathology of diabetic neuropathy is complicated. The main cause of
neuropathy is thought to be hyperglycemia. While glucose pathways are being studied,
multiple other pathways are known to play a role in the onset of hyperglycemia in
patients suffering from diabetes mellitus.12 In diabetes, increased glucose levels may lead
to activation of the protein kinase C pathway. Metabolic pathways such as the polypol,
hexosamine, and inappropriate activation of the protein kinase C pathways cause an
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excess of glycation end products.12,25 The polypol pathway results in the consumption of
NADPH due to the reduction of glutathione, which increases oxidative stress within the
cells.12,25,26 Studies have suggested that over-production of protein kinase C and other
pathological dysregulation of the metabolic processes is thought to play a role in the
over-expression of VEGF and other growth factors, which is thought to lead to
complications such as neuropathy and loss of vascularization.12,25,27,28 The combination of
these pathways leads to an imbalance in the redox state of the mitochondria and an
increase in oxidative stress in the surrounding cells due to an excess formation of reactive
oxygen species, or ROS.12,29 Glutathione is a key compound in the removal of ROS and
restoration of the oxidative state of the cellular environment in the body.12,30 However,
glutathione is not readily available in diabetic patients due to neuropathy and other
complication such as inadequate vascularization, which causes impaired cellular
function.15,31
An estimated 50% of diabetic patients will develop some form of peripheral
neuropathy.12,32 Peripheral neuropathy refers to the damage of nerves in the peripheral
nervous system and the associated loss of sensation, particularly in the extremities.
Nearly 70% of diabetic foot ulcers have some neuropathic association.12,33 Neuropathy
may be categorized into two main groups.12 One type is focal neuropathy, however this
type is not associated with diabetes mellitus. The other type is diffuse neuropathy, which
is the type of neuropathy most commonly associated with diabetes mellitus. Two types of
diffuse neuropathy may accompany diabetes. The first type is distal symmetrical
sensorimotor polyneuropathy, or DPN.12 Symptoms of DPN often occur initially in the
distal portions of the extremities and may then spread in a “stocking and glove”
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formation throughout the extremities.12 Individuals suffering from DPN may have distal
weakness, impaired reflexes, neuropathy, and sometimes neuropathic pain.12 The second
type of diffuse neuropathy is diabetic autonomic neuropathy, or DAN, which is similar in
onset to, and may sometimes accompany, DPN.12 This form of the disease impairs
sympathic and parasympathic autonomic function.12 Diabetic patients are at the highest
risk of developing diffuse neuropathy if there is inadequate glycemic control or they have
had diabetes for a long period of time. If the neuropathy is not brought under control, it
may lead to potentially fatal complications, such as recurrence of the foot infection,
ulceration, or amputation.12
A more effective local drug delivery method could relieve some of these
complications that can often lead to impaired healing and infection if left untreated. If the
diabetic foot ulcer becomes infected, the infection in the soft tissue may spread to the
small bones of the foot, leading to the onset of osteomyelitis. 4,34 The markers of
osteomyelitis are the destruction of the infected bone as well as the formation of seqestra,
which is the separation of devascularized bone fragments caused by ischemic bone
necrosis.34,35 Underlying bone infection accompanies nearly two-thirds of infected
diabetic foot ulcers.35 Nearly 16% of osteomyelitis infected ulcers will end in amputation
and 36% will have a recurrence of the infection.35-37 Inadequate vasculature of long-term
diabetic patients may result in additional complications in the healing and recovery of
osteomyelitis within a foot ulcer.35 It is thought that peripheral neuropathy, vascular
insufficiency, and hyperglycemia put diabetic patients at a higher risk for infection in
general.35 Diabetic foot ulcers that have not undergone appropriate pressure off-loading, a
process by which excessive plantar pressure is relieved through the use of foot gear
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similar to a cast, also pose an increased risk for the development of osteomyelitis and
bone fracture.34 Once an ulcer has become infected, especially if osteomyelitis is
involved, revascularization is essential for the healing and salvage of the limb.35 Some 4
to 6 week long antimicrobial therapies are currently used to treat infected ulcers with
bone involvement.35 The most common treatments currently available for osteomyelitis
are highly invasive and often leave the structure of the surrounding bones weak and the
foot vulnerable to re-ulceration due to the associated changes in pressures and
biomechanics within the foot.34 Although recent studies have found a nearly 85% success
rate may be achieved in the healing of osteomyelitis with the appropriate application of
antibiotics alone,34,38 intravenous therapies are not ideal for this application due to the
impaired vasculature associated with diabetes mellitis.38,39
Adenosine is a compound that has been found to enhance the growth and
proliferation of both fibroblasts and osteoblast-like cells.40,41 Adenosine may have
potential in the healing of osteomyelitis as well as the skin ulceration in diabetic foot
ulcerations. Several in vitro studies have found adenosine to be effective as a growth
stimulator in fibroblasts and osteoblast-like cells.40,41 If an effective local drug delivery
system could be developed, antibiotic treatment combined, with a rigorous off-loading
regimen to decrease plantar pressures on the foot, could prove to be an ideal treatment
method, since it would prevent extreme biomechanical changes in the foot and therefore
reduce the risk of reulceration.34
Neuropathy also leads to decreased function of the fatty pad on the ball of the
foot. Reduction of the fatty pad, in combination with a decreased perception of pain and a
change in biomechanics of the foot due to deep set osteomyelitis, may impair weight-
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bearing and cause excessive stresses on the foot and possibly further injury to the
ulceration.13,23 The decrease in the elasticity of the fatty pad on the ball of the foot leads
to changes in the arch area, causing the arch to lose the ability to absorb pressure, thus
adding to the increased strain of the upper bones of the foot.24 The combination of these
excessive stresses within the metatarsals of the foot along side osteomyelitis may
contribute to the occurrence of fractures within the major bones of the foot, as is common
with diabetic foot ulcers.24 An improved local drug delivery method along side current
clinical treatments could help prevent such an outcome.
1.3.1 Investigation of adenosine and glutathione
Adenosine is being considered for the treatment of diabetic foot ulcers because of
its potential proliferative effects on fibroblasts and other important cells involved in the
healing process. Adenosine is a purine nucleoside found in the DNA of almost all living
organisms.40,42 Adenosine is a component in signaling molecules such as cyclic adenosine
monophosphate (cAMP) and in metabolic molecules such as ATP and ADP. In the body
it also acts at the A1 and A2A adenosine receptor sites to promote wound healing and is
generated at increased rates as a metabolic regulator during periods of high stress due to
injury.42,43 Several in vitro studies have found that adenosine is a growth stimulator for
the proliferation of fibroblasts, which is an important cell type in the dermal healing
process.40,43 However, in diabetic patients, adenosine is not readily available because of
inadequate vascularization in the lower extremities of diabetics.41 Adenosine as also been
implicated as a regulator of the inflammatory immune response.40 Some in vitro studies
suggest that adenosine is even angiogenic, since it stimulates endothelial secretion of
vascular endothelial growth factor, VEGF.25,44 Thus, adenosine could be applied at the
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wound site of a diabetic foot ulcer to promote both fibroblastic growth and to enhance
vascularization at the wound site. Therefore, the use of adenosine as a treatment method
might allow the injury to heal more effectively than current clinical treatments.
Glutathione is being considered for this study because of its importance in the
relieving oxidative stresses that often occur because of inflammation. Glutathione is a
tripeptide and a strong nucleophile that protects the cells in the body against oxidative
damage when in the reduced form.15,31,45 In diabetic patients there is an insufficient
amount of reduced glutathione present to maintain the proper redox potential within the
cells, which delays wound healing in diabetics.16,21 Several clinical studies have found
that reduced glutathione is significantly decreased in diabetic patients.15,31 Previous
studies have also shown that replacing the glutathione in diabetic models promotes
wound healing by restoring the fibroblasts to their natural biological function.16 Since
oxidative stimuli can be produced from the inflammation process, the environment at the
site of a diabetic foot ulcer undergoes increased damage by oxidative stress because the
diabetic patient lacks the reduced glutathione required to protect the cells from oxidative
damage.30 Since adenosine promotes fibroblast proliferation and is an anti-inflammatory
compound, it could be used in conjunction with glutathione to remove the source of
damaging oxidative species, allowing glutathione to bring the environment back to the
proper redox state, and ideally working synergistically with glutathione to promote
fibroblast proliferation.
Previous studies have been performed on the morphology and biological activity
of diabetic fibroblasts.21,46 The hyperglycemic conditions caused by a lack of nutrients at
the wound site in diabetic patients is a major contributor to the change in biological
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activity seen in diabetic fibroblasts. Due to these conditions, the fibroblasts of diabetic
patients, particularly in the lower extremities, undergo slower proliferation and have an
inability to release the necessary growth factors and interleukins to stimulate healing.21 A
study on diabetic fibroblasts at the University of Michigan found that hyperglycemic
conditions present in diabetic wounds lead to defects in fibroblast function, such as
insufficient granulation tissue formation, insufficient epithelialization, and a lack of
wound contraction, due to oxidative stress.21,47 During the study, fibroblasts were
cultured in hyperglycemic conditions, similar to those present in diabetic wounds, and
glutathione was studied as a mechanism for restoring hyperglycemic fibroblasts to
normal glucose conditions.21 Glutathione was found to restore the functionality of
diabetically inhibited fibroblasts to normal wound contraction activity. Several other
antioxidants were studied, but glutathione was found to be the most effective
anitoxidant.21 Since high glucose conditions did not appear to induce apoptosis in
fibroblasts,21 functionality of the fibroblasts affected by hyperglycemia could be restored
with the assistance of glutathione.
1.3.2 Healing process of healthy vs. diabetic wounds
Successful healing requires adequate circulation, nutrition, oxygen level, immune
response, and mechanical stress.48 There are three major phases: inflammation,
proliferation, and remodeling.48 In the inflammation stage, neutrophils and macrophages
are signaled to attack bacteria and debris at the wound site.48 In order for the immune
response to be effective, adequate vascularization is necessary. During the proliferation
and remodeling stages, fibroblasts are responsible for depositing collagen, secreting
growth factors, causing wound contraction, and signaling the migration of other
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important cells, such as kerotinocytes, epithelial cells, and macrophages.5 Without the
migration of these cells, the growth factors and cytokines that they produce will not be
available to maintain the healing process.5 Functional fibroblasts also play an important
role in angiogenesis by releasing vascular endothelial growth factor or VEGF, which
stimulates the construction of new blood vessels. The first three weeks of the healing
process are the most important, as most of the matrix strength is regained in this time.48
In diabetic patients, fibroblasts are often rendered ineffective due to hyperglycemic
conditions and lack of nutrients.21 Therefore, fibroblast function must be restored in order
to achieve adequate healing in diabetic foot ulcers.
Many complications in diabetic foot ulcers stem from impairment in the healing
process at the cellular level.5 Neuropathy caused by diabetes mellitus results in loss of the
protective sensation that would signal pain at the wound site of a normal individual,
leading to increased risk of deep ulceration and infection. Once chronic ulceration and
infection sets in, hyperglycemia and poor vascularization lead to impaired healing and
further complications. Although the major causes of healing impairment in diabetic
wounds is still unknown, several studies have found the cause may be due to a lack of
production of growth factors responsible in the healing process for stimulating the
proliferation and interaction of several cell types involved.17,22 It has been found that in
diabetic fibroblasts collagen production and VEGF release are inhibited.22,25,49-51
Fibroblasts at diabetic ulcer sites have also been found to show decreases in proliferative
and migratory ability.5 Peripheral vascular disease and hyperglycemia are also likely
factors leading to impaired fibroblastic function.22 It is the intention that glutathione and
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adenosine may help assist in the healing of diabetic foot ulcerations by restoring some of
the functionality of these fibroblasts.
1.3.3 Clinical treatment of diabetic foot ulcers
Current treatments for diabetic foot ulcers range from non-invasive surface
treatments with antibiotics to invasive surgery, depending on the extent and classification
of the wound.23 Initial wound care for a foot ulcer involves debridement of necrotic tissue
within the wound, which can cause further injury if healthy tissue must be removed along
side the necrotic tissue.52 Clinicians are also responsible for insuring the environment
surrounding the wound is conducive to proper healing.53 Once the initial steps have been
taken to ensure the stability of the cellular environment within the wound, the ulceration
should be kept moist to promote epidermal migration across the wound bed as well as
angiogenesis.53,54 Wound dressings may be used to assist in the protection and to
maintain the moist environment of the wound base. Several types of dressings may be
used for this application. Saline moistened gauze is the simplest and most common type
of wound dressing currently used to treat diabetic foot ulcers.53,54 Some antibiotic
ointments have been used clinically, but these have not proven to be effective.54 The
incorporation of growth factors, such as PDGF and VEGF, has shown some positive
clinical results, however, growth factors may not result in sufficient healing to justify the
high annual cost of such treatment.5,14,17,25,43,50
Diabetic foot ulcers are also highly susceptible to the involvement of infection. If
infection does occur, the infection is often polymicrobial and difficult to treat.23 In many
studies, systemic antibiotics have proven ineffective under such conditions, likely due to
neuropathy and vascular changes associated with such wounds.54 Off-loading is
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imperative in the treatment of diabetic foot ulcers with deep-set infections, especially if
osteomyelitis is present. Immobilization of the foot is ideal to maintain stabilized cellular
and biomechanical environments adequate for the treatment and healing of the wound.54
The most effective technique for immobilization is total contact casting (TCC), however
this type of system allows only limited access to the wound for dressing changes.54
Splints or therapeutic foot ware may be used instead of TCC to provide better access to
the wound, however improper use and wear by the patient often leads to reinjury of the
foot.54 If inadequate vascularization, due to the nature of the disease, leads to
complications in the effectiveness of treatments, invasive revascularization and
reconstruction of the soft tissue may also be pursued.19,55-58 However, these procedures
may become risky and often do not prevent recurrence of the ulceration. An ideal
treatment would provide the local delivery of healing promoting compounds, while
maintaining a moist and clean environment for the wound. This type of treatment could
be used in conjunction with off-loading therapies and even in combination with
antimicrobial therapies if needed.
1.3.4 Investigation of local drug delivery vehicles
In the past, intravenous delivery systems were used to deliver drugs to wound
sites. However, since intravenous delivery requires the drug move through the blood
stream to arrive at the target area, other areas of the body may be affected by the drug for
extended periods of time, leading to systemic toxicity.9,10 Further more, the drug may
never travel to the wound site, or may not have a high enough effective concentration to
significantly affect the wound.9 In many diabetic wounds, poor vascularization also
inhibits most intravenous drugs from reaching the wound site.9 Therefore, a local drug
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delivery system may be a more effective treatment to achieve a safer delivery of the
appropriate drug at higher, more effective local concentrations.9,59 Current local drug
delivery systems include bone cement, calcium sulfate, polylactic acid (PLA),
polyglycolic acid (PGA), collagen, and chitosan.9,10,59,60 The material for a drug delivery
vehicle should be selected based on the application and drug type. Since the main focus
of diabetic wound treatment is damaged soft tissue surrounding the ulceration, the
material should also be similar in mechanical properties to soft tissue.54,61 The optimal
local delivery vehicle would be used in combination with a wound dressing for foot ulcer
treatment and the delivery device used should be able to maintain a moist environment
and should have regenerative abilities. In the diabetic foot ulcer, it is especially important
the compounds used during treatment can be maintained for at least a three to seven day
time period, since wrappings are typically changed and revised in 3 to 7 days.53,54
Concentrations of therapeutic agents, such as glutathione and adenosine, should
be released locally at biologically safe and effective dosages from drug delivery devices.
Glutathione and adenosine should have a targeted release at initial concentrations of
approximately 250 µM and 500 µM, respectively, based on experimentation and known
biological concentrations in the body.5,15,21,62,63
1.3.5 Chitosan as a local drug delivery system
Chitosan is a biodegradable polysaccaride bipolymer that comes from the
exoskeletons of crustaceans.64,65 Chitosan is a naturally derived biomaterial that has been
shown to be biocompatible and biodegradable.9,66-68 An advantage of using chitosan as a
local drug delivery vehicle is its ability to be engineered to have particular degradation
and elution properties, as needed.9,67 For diabetic ulcers, chitosan could be effective
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because of its biocompatibility and its ability to be customized.9 Different properties may
be achieved by changing the percent of deacetylation, the acid content, and the molecular
weight of the chitosan material used in a drug delivery device. Chitosan constructs can
also be engineered as gel, bead, film, and sponge constructs which may be cross-linked or
not cross-linked.9,43,67 Furthermore, several studies have found that chitosan itself has
hemostatic properties and also enhances wound healing rate.69-71 The wound healing
properties of chitosan are thought to be largely due to biodegradability as well as the
monomeric unit N-acetylglucosamine contained within the chitin building blocks of
chitosan. This monomer also occurs in hyaluronic acid, an important macromolecule in
wound repair, making chitosan a promising biomaterial for promoting accelerated
healing.70,72 In this proposed study, a sponge construct was used to achieve the targeted
elution of adenosine and glutathione for local delivery to a diabetic wound site.
1.3.6 Purpose of study
In this preliminary in vitro study, the effectiveness of an adenosine and
glutathione loaded chitosan sponge delivery system on the biological activity of dermal
fibroblasts was evaluated. The goal was to investigate the combination of two growthpromoting compounds in a chitosan local drug delivery system for their ability to produce
an enhanced fibroblastic response in vitro. The study hypothesis is that fibroblastic
function and matrix formation can be enhanced through the application of compounds
naturally occurring in the body via an optimized localized drug delivery system. The
sponge construct design of the delivery system would allow for direct application of the
treatment at the wound while still allowing for a moist wound dressing, thereby
eliminating the risk of systemic toxicity while integrating with current diabetic wound

14

!

dressing methods. The compounds would add the benefit of decreasing the oxidative
stress within the wound and improving fibroblastic function of the treated cells. The
result would be improved healing of the wound and ideally a decrease in the recurrence
of ulceration.
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CHAPTER 2
INCORPORATION OF WOUND HEALING AGENTS INTO CHITOSAN
SPONGES TO PROMOTE HEALING OF DIABETIC FOOT ULCERS
2.1 Introduction
Diabetes mellitus affects approximately 20.8 million people annually in the
United States alone.1,2 Nearly 15% of these diabetic patients will suffer from a diabetic
foot ulcer with 20% of foot ulcers ending in amputation.1,3-5 The five-year survival rate
for a diabetic amputee is 31%.6,7 Annual costs of healthcare for diabetic foot ulcer
complications can be as high as $10.9 billion.8,9 Difficulties in treatment also arise due to
the neuropathy and insufficient vascularization associated with the disease.10 Reduction
of the fatty pad, in combination with a decreased perception of pain, may also impair
weight-bearing, thereby causing excessive stresses on the foot and eventually ulceration
or further injury to a previous ulcer.10,11 These complications and a reduction in the
presence of important natural growth promoting compounds, such as vascular epithelial
growth factors, platelet derived growth factors, adenosine, and glutathione, cause the
healing of diabetic foot ulcers to be difficult.12-15
The presence of hyperglycemia also increases the likelihood that an individual
will develop a foot ulceration.16,17 Diabetic patients also suffer from poor vascularization,
especially in the lower extremities.4,10,18 This pathology leads to an inability for the
proper growth factors and other growth promoting compounds to be transported to the
wound site to assist in healing.4,10 As the disease progresses, these complications may
lead to a loss of integrity of the fatty pad and skin on the bottom of the foot.10,19,20 Further
complications may even lead to bone degradation and fracture in the large metatarsals of
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the foot. Successful healing requires adequate circulation, nutrition, oxygen level,
immune response, and mechanical stress.21 During wound healing, fibroblasts are
responsible for depositing collagen, secreting growth factors, causing wound contraction,
and signaling the migration of other important cells, such as kerotinocytes, epithelial
cells, and macrophages.6 Without the migration of these other important cells, the growth
factors and cytokines they produce will not be available to maintain the healing process.6
In diabetic patients, fibroblasts are often rendered ineffective due to hyperglycemic
conditions, lack of nutrients, and oxidative damage.16 Therefore, fibroblast function must
be assisted in order to achieve adequate healing in diabetic foot ulcers. Furthermore,
osteoblast migration and function is essential in the healing process since many diabetic
foot ulcerations are accompanied by bone infection known as osteomyelitis which can
lead to bone fracture.
In this study, we hypothesized that two compounds, adenosine and glutathione,
may be used to enhance fibroblastic response in a diabetic in vitro model. Adenosine is a
purine nucleoside found in the DNA of almost all living organisms.22,23 In the body it also
acts at the A1 and A2A adenosine receptor sites to promote wound healing and is
generated at increased rates as a metabolic regulator during periods of high stress due to
injury.22 Several in vitro studies have found adenosine has a positive impact on fibroblast
proliferation and wound healing.24,25 However, in diabetic patients, adenosine is not
readily available because of inadequate vascularization in the lower extremities.24 In vitro
studies have also found that adenosine is angiogenic, since it stimulates endothelial
secretion of vascular endothelial growth factor, VEGF.25
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Glutathione is a tripeptide and a strong nucleophile that protects the cells in the
body against oxidative damage when in the reduced form.12,26,27 In diabetic patients there
is an insufficient amount of reduced glutathione present to maintain the proper redox
potential within the cells, which delays wound healing in diabetics.13,16 Several clinical
studies have found that reduced glutathione is significantly decreased in diabetic
patients.12,27 Previous studies have also shown that replacing the glutathione in diabetic
models promotes wound healing by restoring the fibroblasts to their natural biological
function.13
In diabetic wounds poor vascularization also inhibits most intravenous drugs from
reaching the wound site. Therefore, a local drug delivery system could achieve a more
effective delivery of the appropriate drug at higher local concentrations.28-30 In the
diabetic foot ulcer, it is especially important the compounds used during treatment can be
maintained from the local delivery vehicle for at least a three day time period, since the
foot ulcer dressings are changed on a three to seven day cycle.31 The proposed drug
delivery mechanism must also allow for controlled drug loading and release.6,12,16,32,33
The natural polysaccharide biopolymer chitosan has advantages for local drug
delivery to diabetic foot ulcers because of its biocompatibility and ability to be
customized.34,35 Degradation and delivery properties may be controlled by changing the
percent of deacetylation as well as the acid content of the chitosan construct.36,37 Chitosan
constructs can also be engineered as gel, bead, film, and sponge constructs which may be
easily applied as a moist wound dressing.28,36-38 A sponge construct was chosen for this
study for its potential ability to achieve the targeted elution of adenosine and glutathione
for local drug delivery to a diabetic wound site.
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The purpose of this study was to investigate the co-delivery of both growthpromoting compounds delivered from a chitosan-based local drug delivery system for
their ability to enhance fibroblast proliferation and collagen production. It is possible that
fibroblastic function and matrix formation can be enhanced through the application of
compounds naturally occurring in the body via a localized drug delivery system. Since
adenosine promotes fibroblast proliferation and is an anti-inflammatory compound, it
could be used in conjunction with glutathione to remove the source of damaging
oxidative species, allowing glutathione to bring the environment back to the proper redox
state, and promote fibroblast proliferation and tissue repair. The sponge construct design
of the system would allow for direct application of the treatment at the wound while still
allowing for a moist wound dressing, thereby minimizing the risk of systemic toxicity
while integrating with current diabetic wound dressing methods. The selected compounds
would add the benefit of decreasing the oxidative stress within the wound while
improving the fibroblastic response, which could potentially decreasing the recurrence of
ulceration by improving the rate and quality of wound healing.
2.2 Materials and Methods
2.2.1 Seeding and analysis of cellular proliferation
Normal human dermal fibroblasts (NHDF) (Cambrex BioScience; Walkersville,
MD) were plated at 1x104 cells per cm2 in 96 well polystyrene tissue culture plates (BD
Falcon; Franklin Lake, NJ) to evaluate cell proliferation. NHDF cells were used from
passages 3 through 8 and suspended in Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and 100 µg/ml of the antimicrobial
Normocin™ (Invivogen) for initial evaluation and proliferation. All fibroblasts in this
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proliferation study were seeded and allowed to proliferate in standard culture conditions
(37oC, 5% CO2 atmosphere) overnight (n=4). Fibroblasts were then serum starved for 24
hours and then exposed to a two-fold dilution of either 1000 µM adenosine or 500 µM
glutathione. Fibroblast proliferation was analyzed after 24 hours of exposure to adenosine
or glutathione solutions using the Cell Titer-Glo Luminescence Cell Viability Assay
(Promega Corp.;Madison, WI). Briefly, cells were exposed to the compound for 24 hours
to elicit a response, and then culture media was removed from all wells and replaced with
100 µl of serum-free DMEM and an equal volume of reconstituted Cell Titer-Glo reagent
solution. The luminescence signal corresponding to the amount of the metabolic molecule
adenosine triphosphate (ATP) present was obtained and the emission was recorded using
a 96-well plate reader at 590 nm (Bio-Tek Inst. Inc., Model No. FLx800; Ontario,
Canada) in conjunction with data analysis computer software (kinecticalc
KC4 v3.4Rev.16; Ontario, Canada). Results were reported as luminescence emission
®

(LRU) and compared to non-treated controls. A secondary evaluation was also conducted
to determine the potential effects of adenosine and glutathione on bone healing. In this
preliminary study, normal MC3T3 osteoblast-like cells (Sigma-Aldrich; St. Louis, MO)
were plated at 1x104 cells per cm2 in 96-well polystyrene tissue culture plates (n=4).
Cells were used from passages 3 through 5 and suspended in alpha-MEM supplemented
with 10% FBS and 100 µg/ml of the antimicrobial Normocin™. A proliferation study was
performed under standard cell culture conditions following the same procedure as was
used for NHDF proliferation. The Cell Titer-Glo Luminescence Cell Viability Assay was
also used to evaluate MC3T3 cell proliferation and reported similarly to fibroblast
evaluation.
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2.2.2 Seeding and analysis of fibroblast collagen production
To evaluate the effect of adenosine or glutathione on collagen production,
fibroblasts were plated at 1x106 cells per cm2 in 24-well polystyrene tissue culture plates
from passages 3 through 8. Only fibroblasts were chosen for this study since they are the
primary cell type responsible for collagen production in the wound healing process.
Fibroblasts were suspended in media containing varying concentrations of D-glucose to
represent different degrees of diabetic and normal glucose conditions, with 5mM and
25mM being considered low and high normal glucose conditions, and 35mM glucose
being considered diabetic cellular glucose levels based on a study by Devici.16 All media
was supplemented with 10% FBS and 100 µg/ml of the antimicrobial Normocin™.
Fibroblasts were cultured in 5, 25, or 35 mM glucose conditions and standard culture
atmosphere conditions for at least 3 passages to establish the targeted glucose condition.
Once plated, fibroblasts were allowed to attach for 24 hours and then exposed to 500 µM
adenosine, 250 µM glutathione over a 12 day time period (n=5). In a separate experiment,
fibroblasts were exposed to medium containing 250 µM glutathione for 3 days, and then
medium containing 500 µM adenosine for 9 days. This time sequenced exposure to
glutathione previous to adenosine was intended to bring the oxidative stress back to
normal conditions for hyperglycemic fibroblasts as seen in a study by Deveci et al.16
A comparison collagen production evaluation of hyperglycemic fibroblasts versus
normal fibroblasts was determined after the exposure experiments using the colorimetric
Sircol™ Soluble Collagen Assay (Biocolor Ltd; Northern Ireland, U.K.) using standard
protocols.39 Absorbance measurements were taken at 555nm using a spectrophotometer
(SPECTRAmax Pro 4.8, v3.05). Samples were compared to collagen Type I (Biocolor)
®
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reference standards. DNA was also quantified after the discussed adenosine and
glutathione exposure experiments using the Quant-iT PicoGreen kit (Invitrogen;
Carlsbad, CA) following standard protocols.40 Results of the collagen comparison
evaluation were normalized to dsDNA and reported as amounts of collagen/dsDNA
([µg/ml]/[ng/ml]).
2.2.3 Chitosan sponge fabrication
Chitosan with 71% degree of deacetylation (DDA) (Primex; Siglufjordur, Iceland)
was measured to 2.5g and dissolved in a 1% (v/v) acid solution (75/25 lactic/acetic
acid)(Fisher Scientific). The chitosan sponges were cast in 5 cm diameter aluminum
weigh dishes, placed in a -80oC freezer for 24 hours, and lyophilized in a Lab Conco
freeze dryer. After 45 – 50 hours, the sponges were removed from the freeze dryer and
neutralized by immersing in 0.5 M NaOH or acetate buffer followed by washing in
distilled water. Neutralized, saturated sponges were then placed back into the weigh
dishes, re-frozen at -80oC for 12 hours, and re-lyophilized for 18 – 24 hours. Sponge
constructs were packaged in sterilization pouches and sterilized using low-dose 25 kG
gamma irradiation.
2.2.4 Elution study
Sterilized chitosan sponges (approximately 38mm diameter x 3mm thickness)
were loaded by immersion in approximately 10 ml of 1000µM (267.2 µg/ml) adenosine
(Sigma-Aldrich) or 500µM (153.7 µg/ml) glutathione (Sigma-Aldrich) for 1 minute.
Immediately after uptake five replicates (n=5) of adenosine loaded and four replicates
(n=4) of glutathione loaded sponges were completely submerged in 15 ml sterile filtered
phosphate buffer saline (PBS) in sterile Nalgene containers. The loading concentrations
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used for the treatment solution were increased by a factor of two compared to optimal
dose concentrations found in the preliminary cell proliferation studies. This two-fold
increase was intended to account for the dilution of the compounds when submerged in
PBS during elution as well as to allow for continued release of viable concentration over
a three-day elution study. 1 ml samples were taken at 24-hour intervals (24, 48, and 72
hour sample time points). PBS was completely replaced after each sampling. All chitosan
sponge samples were normalized to initial dry weight by dividing the detected adenosine
or glutathione concentration by the initial dry weight of the associated chitosan sponge.
Concentrations of adenosine in eluate solutions were determined using a HPLC technique
adapted from Porkka-Heisanen et al.41 Briefly, adenosine elution samples were injected
into a Varian Microsorb-MV C18 normal phase column in a mobile phase of 0.01M
K2HPO4 in 10% MeOH adjusted to a pH of 4 using phosphoric acid and sodium
hydroxide. Peaks were detected at a wavelength of 256 nm at 5 minutes and quantity was
determined by comparing to a standard curve. Concentrations of glutathione were
determined using a Glutathione assay kit (Sigma-Aldrich). Briefly, monochlorobimane, a
thiol probe, was used to bind to reduced glutathione. This reaction, catalyzed by
glutathione-S-transferase, can be used to detect the amount of reduced glutathione present
by measuring fluorescence. The effect of eluates on proliferation of fibroblasts was
evaluated using the Cell Titer-Glo assay as described above.
2.2.5 Statistical analysis
Quantitative data were expressed as the mean ± standard deviation (n ≥ 4 for all
groups). Statistical differences in elution profiles between similar samples were
determined using two-way analysis of variance (ANOVA) with Tukey’s Honest
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Significant Difference post-test. A student t-test was used to determine significant
differences of samples in the dose response studies, the collagen production studies, and
the elution biological response studies. A p-value < 0.05 was considered statistically
significant for all experiments.!
2.3 Results
Initial proliferative activity showed a dose-dependent increase in fibroblast
response to the addition of adenosine or glutathione at concentrations up to 500 µM
(133.6 µg/ml) or 250 µM (76.8 µg/ml), respectively (Figure 1A). Furthermore,
concentrations of adenosine exceeding 125 µM (33.4 µg/ml) showed an increase in
proliferative response of MC3T3 osteoblast-like cells. Glutathione appeared to have no
advantageous effects on MC3T3 osteoblast-like cells (Figure 1B). However, the results
suggest that levels of glutathione higher than 500 µM (153.7 µg/ml) may have adverse
effects on fibroblast proliferation and glutathione may also have an adverse effect on
osteoblast-like cells.!
Adenosine, glutathione, and a combination treatment were evaluated on
fibroblasts for collagen production to determine the potential additive or synergistic
effects in fibroblast stimulation (Figure 2). The addition of 250 µM (76.8 µg/ml)
glutathione in combination with 500 µM (133.6 µg/ml) adenosine produced the greatest
response, with collagen production increasing nearly three-fold on the third day
compared to the control group.
To gain a better understanding of the effects of exposing fibroblasts to adenosine,
glutathione, or a combination of both compounds, DNA and collagen were measured
independently as shown in Figure 3A and 3B. These results suggest that exposure to
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these compounds resulted in a decrease in proliferation of fibroblasts at day 3 and 6 with
a slight increase in proliferation for the adenosine and combination groups at day 12
compared to the control group. However, collagen production results suggest that the
amount of collagen produced versus the amount of DNA present is increased by exposure
to the compounds for days 3 and 6 compared to the control (Figure 2 and 3).
Collagen synthesis was also tested for diabetic induced fibroblasts (Figure 4).
Glutathione and adenosine dosage in combination resulted in the greatest response of
fibroblast function to produce collagen matrix for normal conditions at 5 mM and 25 mM
glucose concentration over a 12-day period. However, fibroblasts grown under high
glucose conditions of 35 mM glucose intended to simulate the diabetic cellular
environment were not restored to normal function, contradictory to the hypothesis.16
The addition of glutathione combined with adenosine dosage induced the highest
response in collagen production for both 5 mM and 25 mM glucose, however neither the
addition of adenosine nor the combination of adenosine and glutathione elicited an
increase in collagen production for 35 mM glucose. The response of fibroblasts in
diabetic-stimulated environments suggests that at moderate levels of increased glucose
concentration the combination of adenosine and glutathione could improve fibroblast
function and healing. However, at higher levels of glucose (35 mM) this effect is
diminished, suggesting that this treatment may only be successful if glucose levels are
closely managed.
DNA and collagen production were also measured individually to better
determine the effects of the compounds on hyperglycemic fibroblasts (Figure 5). These
results show that adenosine had the greatest effect on fibroblast proliferation over the 12-
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day period. However, proliferation was still not fully restored for the 35 mM glucose
hyperglycemic group. Results also showed that collagen production increased for the
group exposed first to glutathione followed by adenosine under 5 mM glucose and 25
mM glucose conditions. However, collagen production was not restored in the 35 mM
glucose group.!
Elution of adenosine from sponge constructs (Figure 6) showed an initial burst
release of adenosine at 24 hours, followed by significantly lower release concentrations
after 48 hours. Adenosine eluted from chitosan sponges appeared to maintain significant
levels of biological activity at 24 and 48 hours (Figure 7).!
Elution of glutathione from chitosan sponge constructs (Figure 8) showed an
initial burst release of glutathione at 24 hours, followed by significantly lower release
concentrations after 48 hours. Glutathione eluted from chitosan sponge constructs also
appeared to show trends toward increased fibroblast proliferation, however no significant
increases were detected at any sample time points (Figure 9).!
2.4 Discussion
The objective of this preliminary in vitro study was to determine if local delivery
of adenosine and glutathione could be considered as a therapeutic approach to improve
the treatment and healing of diabetic foot ulcers. Many current treatments used to
improve the impaired healing of diabetic ulcerations require the use of growth factors,
which are expensive and can be relatively ineffective in the overall healing of these type
of wounds.14,31,42,43 Based on these preliminary results, the use of adenosine, a common
nucleoside, and the tripeptide glutathione, may potentially promote the wound healing
process. In foot ulcers with controlled glucose levels, the use of a chitosan sponge
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construct could provide the local delivery vehicle for active healing agents and the moist
environment needed for proper healing of these healing impaired wounds.
Our study found adenosine alone to effectively increase fibroblast proliferation
response within a window of 125 to 2000 µM (33.4 to 534.5 µg/ml) and glutathione alone
to be effective within a window of 62.5 to 250 µM (19.2 to 76.8 µg/ml). However, at
levels of glutathione higher than 500 µM (153.7 µg/ml), this study suggests that
glutathione may in fact have adverse effects on fibroblast proliferation. In a study by
Victor-Vega highly selective adenosine receptor agonists were effective at all
concentrations tested. However, the less selective receptor agonist lost its capacity to
promote rapid wound closure at higher and lower end dosage concentrations (10 and 0.5
µg/wound).43 This study partially confirms the results found in the Victor-Vega study
since short-term dosage of adenosine showed significant activity at 24 hours and
concentrations between 125 and 1000 µM (33.4 and 267.2 µg/ml).43 A study by Ohana
also confirmed that adenosine regulates cellular proliferation of many cell lines at low
concentrations (4 µM or 1.07 µg/ml).22 Our study similarly found adenosine to have a
narrow window of efficacy on osteoblast-like MC3T3 cell proliferation at concentrations
between 125 and 2000 µM (33.4 and 534.5 µg/ml over short-term exposure. This data
also confirms similar findings by Shimegi that showed at a concentration of 100 µM
adenosine (26.7 µg/ml), MC3T3-E1 osteoblast-like cell proliferation and DNA synthesis
were stimulated in a dose dependent manner.44 Since many foot ulcers include infection
and osteolysis of the larger bones in the foot, it is significant that adenosine is a stimulant
for both dermal and osteoblastic cell proliferation.10
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Furthermore, the combination of glutathione and adenosine added to fibroblasts
resulted in a synergistic increase in fibroblastic collagen production at day three of the
twelve day study on normal fibroblasts. This increase in collagen production per DNA
present suggests that the addition of glutathione and adenosine in combination can
improve the function of fibroblasts to deposit collagen needed for defect filling in the
wound healing process. Although adenosine alone induced a higher proliferative response
in dermal fibroblasts, the addition of glutathione may assist not only in the stimulation of
collagen formation but also as a preliminary compound to remove oxidative stress present
due to hyperglycemia intrinsic in diabetes mellitus.52,53 This potential was seen in the
additive effect that the time sequenced combination exposure had on collagen production
of normal fibroblasts grown in 5 mM glucose and hyperglycemic fibroblasts grown in 25
mM glucose. However, the diabetic fibroblasts grown in concentrations of glucose
exceeding 35 mM were unresponsive to the treatments in this study, suggesting that this
treatment is only effective for patients undergoing close monitoring and control of
glucose levels. A similar study by Deveci et al suggested that the addition of glutathione
is affective in restoring the collagen contractility of fibroblasts that were previously
grown in high glucose conditions representative of hyperglycemia similar to the
conditions in this study.16 However, it should be noted that our preliminary study
evaluates the production of collagen necessary for matrix formation rather than the
contractility of collagen after healing begins, which is the focus of the Deveci study.
The most common local drug delivery system currently in use clinically is the
incorporation of antibiotics into polymethylmethacrylate (PMMA) beads.45 However, one
major disadvantage of PMMA, which is non-degradable, is the necessity of removal after
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the initial wound has healed.45 In diabetic foot ulceration therapy, the growth factor
containing hydrogels, such as Becaplermin (Regranex, Johnson & Johnson, New
Brunswick, NJ), are available for topical treatment of ulcerations.1,11,14 However, growth
factors may not result in sufficient healing to justify the high annual cost of
treatment.1,11,14 Results from this preliminary study suggest chitosan, a biodegradable
bipolymer, may be an effective local drug delivery vehicle.28,36,45-47 A study by Noel et al
demonstrated that degradable chitosan film can be engineered to locally release an
antibiotic over a period of 72 hours and that the released compound remains active.28,36
Similarly, chitosan constructs released active amounts of gentamycin over a 2 week
period in a study by Aimin et al.45 A study by Parker et al also suggest that cross-linked
chitosan may be a solution for a more predictable elution profile with minimal burst
release.36 Results of this preliminary study indicate that the biological activity of
adenosine incorporated into chitosan sponges is maintained at 24 and 48 hour time points.
However, eluted glutathione did not show any significant increase in fibroblast
proliferation. Further experimentation is required to determine if this minimal response is
related to a loss of biological activity in the compound itself or the high burst
concentrations of the eluted compound. A study by Kirk et al also suggests that
crosslinking within a collagen local drug delivery material minimizes the burst release of
eluted compound.48 Similar chitosan studies found the material to have minimal cytotoxic
effects on normal human dermal fibroblasts as well as healing properties during wound
repair.43,47,49,50 Ueno et al found that the application of chitosan in an in vivo wound
model resulted in improved healing over the 15 day study.50 Based on the results of this
preliminary study and the findings of similar studies by Noel, Parker, and Aimin,
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chitosan is a promising biomaterial for use as a local drug delivery vehicle and my be a
good candidate for this local drug delivery application.28,36,45,47,51 Specifically, since
current foot dressings require a clean, moist environment to assist in healing, the chitosan
sponge construct would best provide the desired environment while still maintaining a
desirable elution profile, since a sponge will retain water thereby keeping the wound
moist.
Based on the findings in this preliminary in vitro study, adenosine and glutathione
show promise as compounds to improve healing of impaired wounds under conditions in
which glucose levels are closely monitored and controlled. Results for the effect of
adenosine on osteoblast-like cells also suggest that further experimentation would be
beneficial to explore the potential of adenosine to improve the bone healing response, as
might be needed in an infected diabetic foot ulcer.54-56 Future experimentation should
include in vivo evaluations of other possible applications of adenosine and glutathione
and local drug delivery with a chitosan sponge. Furthermore, a diabetic animal model
might reveal the full potential of an adenosine and glutathione therapy for its use as a
clinical treatment for healing-impaired injuries.
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CHAPTER 3
CONCLUSIONS AND FUTURE WORK
This preliminary in vitro study found that individual doses of adenosine and
glutathione improved the proliferation of normal human dermal fibroblasts. Adenosine
also had positive affects on osteoblast-like MC3T3 cells at concentrations higher than 30
µM in vitro. Since osteoblast-like cells responded favorably to adenosine treatments,
further in vitro experimentation should be performed to explore the potential use of
adenosine in bone restoration applications. The combination of adenosine and glutathione
also improved collagen production by fibroblasts grown under normal conditions.
Furthermore, these compounds can be individually incorporated into separate chitosan
sponge constructs for local drug delivery at a foot ulceration site, while providing a moist
and clean environment adequate for the wound healing process. However, in vitro results
showed that chitosan sponges resulted in some decreased cellular response compared to
direct application, possibly due to activity loss from the incorporation elution of
adenosine and glutathione from the sponges. Therefore, further work is necessary to
determine and improve the elution of the active eluates from the sponges.
The combination of these compounds resulted in an increase in collagen
production by fibroblasts in vitro. However, the other migratory cell types, such as
keratinocytes and endothelial cells, present in a true representation of a clinical wound,
may also be affected by these compounds and wound healing. These cell types should
also be investigated with adenosine and glutathione. Studies have found that adenosine
has angiogenic qualities.44 Therefore, an in vitro assessment of an adenosine and
glutathione loaded sponge could be tested in a trans-well migration assay to determine

36

!

the chemotactic, proliferative, and angiogenic properties of adenosine and glutathione
released from chitosan sponges. In this way, a more accurate assessment can be made
about the effects of glutathione and adenosine on the complex healing process. Measured
production of growth factors such as VEGF might further clarify the possible
effectiveness of a glutathione and adenosine therapy to restore vascularization of healingimpaired wounds.
In this preliminary study, glutathione and adenosine showed many promising
results both separately and in combination. Further exploration of time dependent and
dose dependent releases of the compounds could provide better characterization of the
applications for which adenosine and glutathione may be used. Furthermore, a study on
the effects of adenosine and glutathione on collagen contraction in diabetic fibroblasts
would provide a better understanding of how the compounds enhance healing in
combination. Finally, a diabetic wound animal model, such as the diabetic rat model
utilized by Zhao et al or the dog wound model utilized by Ueno et al,71,73 would
demonstrate the full effectiveness of adenosine and glutathione as a treatment for healingimpaired injuries and possibly as an angiogenic therapy. The effectiveness of this therapy
in an animal model would provide evidence to its use in clinical treatments of chronic
and impaired wounds.
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APPENDIX A
CHITOSAN FILM PRELIMINARY STUDY
Introduction
For future reference, the following is included to provide results of a preliminary
study on chitosan films. Initial testing was performed on chitosan films, but it was
determined that a sponge construct would better provide the environment necessary for
the healing process. A sponge construct would also be more compatible with current
treatment and wound dressing methods, as discussed earlier in this manuscript.
Materials and Methods
Chitosan film fabrication
Chitosan with 80% degree of deacetylation (DDA) (Primex; Siglufjordur, Iceland)
was measured to 5g and dissolved in 250mL of a 1% (Lactic or Acetic) (Fischer
Scientific) acid solution containing 2 mM adenosine. The chitosan films were cast into 9
cm diameter glass Petri dishes at a volume of 50 ml in each dish and allowed to dry for
18 – 24 hours at 37oC in a convection oven. Films were then removed from the dishes
and neutralized to a pH of 6 to 7 in 2M NaOH and washed in distilled water. Films were
then allowed to dry at low heat (30 – 40oC) for 16 – 20 hours in a convection oven.
Elution study
Sterilized chitosan film constructs (9cm diameter) loaded with 1000µM
(267.24µg/ml) adenosine (Sigma-Aldrich) were completely submerged in 20ml sterile
filtered phosphate buffer saline in 9cm glass Petri dishes at 37oC. The elution study was
performed over a three-day time span with samples taken at 24, 48, and 72 hours. Elution
media was completely replaced after each sampling. Concentrations of adenosine in

44

!

eluate solutions were determined using HPLC technique from Porkka-Heisanen et al as
discussed previously.73 All chitosan film samples were normalized to initial dry weight
by dividing the detected adenosine concentration by the initial dry weight of the
associated chitosan film.
Analysis of fibroblast proliferation
Analysis of fibroblast proliferation was performed similar to the technique
described in the body of this manuscript.
Results
Release results of adenosine elution from the chitosan films showed an initial
burst release of adenosine from lactic acid and acetic acid solvent films at 24 hours
followed by significantly lower release after 48 hours (Figure 10). More total adenosine
eluted from the chitosan films made with acetic acid solvent than from films made with
lactic acid solvent. Samples were normalized to the initial weight of the chitosan films.
Initial analysis of activity of eluates indicates significant increases in proliferation
from both sets of film samples tested (Figure 11).
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Figure 1. (A) Dermal fibroblast and (B) osteoblast-like cell
proliferation cultured in the presence of adenosine and
glutathione over a 24-hour exposure period. n=4 for all
groups. (*=p<0.05; **=p<0.001; as compared to control)
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Figure 2. Dermal fibroblast collagen production induced by the
addition of adenosine, glutathione, or a combination of both over a
12-day period. Collagen production was normalized to DNA
content. n=5 for all groups. (*=p<0.05 compared to control)
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Figure 3. Dermal fibroblasts were exposed to 500 µM adenosine,
250 µM glutathione, or a combination of both compounds over a
12-day study. (A) Fibroblast proliferation represented as ng/ml
dsDNA. (B) Collagen production represented as µg/ml collagen.
n=5 for all groups. (*=p<0.05 as compared to control)
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Figure 4. Dermal fibroblast collagen production induced by the addition of
adenosine or of glutathione combined with adenosine compared against
normal and hyperglycemic fibroblasts over a 12-day period. n=4 for all
groups. (*=p<0.05 compared to control)
!

50

!

A.

'&!"
DMEM
'%!"

Glutathione/Adenosine
Adenosine

'$!"

*

dsDNA (ng/ml)

'#!"
'!!"
&!"

*

%!"
$!"
#!"
!"

5mM glucose

25mM glucose

100

B.

DMEM

90

Glutatihone/Adenosine

Collagen (ug/ml)

60

Adenosine

**

80
70

35mM glucose

*

**
**

50

*
*

40

**

30
20
10
0
5mM glucose

25mM glucose

35mM glucose
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Figure 6. Concentration of adenosine released from
chitosan sponges over a 72-hour period.
Concentration was normalized to µg/ml adenosine per
gram dry weight chitosan. n=5
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Figure 7. Dermal fibroblast proliferation cultured in
the presence of adenosine elution samples from
chitosan sponges over a 72-hour period. Cellular
proliferation is measured in luminescence. n=5
(*=p<0.05 compared to DMEM control)
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Figure 8. Concentration of glutathione released from chitosan
sponges over a 72-hour period. Concentration was normalized to
µg/ml glutathione per gram dry weight chitosan. n=4 for all groups.
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Figure 9. Dermal fibroblast proliferation cultured in the
presence of glutathione elution samples from chitosan
sponges over a 72-hour period. Cellular activity is measured
in luminescence. n=4 for all groups.
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Figure 10. Concentration of adenosine released from chitosan
film over a 72-hour period. Concentration was normalized to
µg/ml adenosine per gram dry weight chitosan. n=7
(*=p<0.05 comparison)
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Figure 11. Dermal fibroblast activity cultured in the
presence of adenosine elution samples from chitosan film
constructs over a 72-hour period. Cellular proliferation is
measured in luminescence. n=7 (*=p<0.05 compared to
DMEM control)
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